У нас вы можете посмотреть бесплатно Pondering GLP-1 Receptor Agonists for Parkinson’s Disease with Tom Foltynie или скачать в максимальном доступном качестве, которое было загружено на ютуб. Для скачивания выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса savevideohd.ru
When we eat a meal containing carbohydrates a peptide called GLP-1 is released into the blood and acts in several ways to improve glucose regulation. It stimulates insulin release from the pancreas, increases insulin sensitivity, and suppresses appetite. A peptide called exenatide originally discovered in the venom of the Gila monster activates GLP-1 receptors and is now prescribed as a treatment for diabetes and obesity. Preclinical studies at the NIH showed that exenatide prevents neuronal damage and improves functional outcome in experimental models of Parkinson’s and Alzheimer’s diseases. Professor Tom Foltynie at University College London then led clinical trials of exenatide in Parkinson’s disease which demonstrated beneficial effects of exenatide. In this episode I talk with Professor Foltynie about GLP1 receptor agonists and how they protect neurons against damage and dysfunction in Parkinson’s and other neurological disorders. LINKS Professor Foltynie’s webpage: https://www.ucl.ac.uk/ion/research/ou... Lancet article: RCT of Exenatide in Parkinson’s disease: https://www.ncbi.nlm.nih.gov/pmc/arti... Review articles on GLP1 and its effects on diabetes and obesity https://www.cell.com/action/showPdf?p... Review article on energy metabolism and Parkinson’s disease: https://content.iospress.com/download... Preclinical studies of Exenatide for: Parkinson’s disease: https://www.ncbi.nlm.nih.gov/pmc/arti... Alzheimer’s disease: https://www.ncbi.nlm.nih.gov/pmc/arti... Huntington’s disease: https://www.ncbi.nlm.nih.gov/pmc/arti...